Table 3 Overall response rates adjusted for matching.

From: KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Responsea

Matched KarMMab (N = 76–80c)

Matched Eligible RRMM cohort (N = 76–80c)

ORR (95% CI), %

71.6 (61.5–83.3)

29.4 (20.2–42.8)

 RR (95% CI)

2.4 (1.7–3.6)

 P

<0.0001

  1. ORR overall response rate, RR risk ratio.
  2. aDerived for Matched Eligible RRMM and Matched KarMMa cohorts using greedy nearest neighbor matching with a caliper of 0.2 standard deviation of logit of the propensity score.
  3. bAcross all target doses.
  4. cNumber (range) of matched subjects from 30 imputed datasets; greedy nearest neighbor matching with a caliper.
Back to article page